Prothena Corporation plc's phase 3 trial failure in AL Amyloidosis was a setback, but Alzheimer's & Parkinson's data could ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids ...

BMY stock offers value with a sub-7x P/E, 6% dividend yield, and strong earnings. Discover why it’s a compelling buy despite ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

McKesson MCK and Cardinal Health CAH are two of the largest healthcare distribution companies in the United States, playing a ...

Charles R. Goulding and Aaron Rofe reveal how industry leaders like Eli Lilly, Johnson & Johnson, and Roche are going all-in ...

The voluble billionaire discusses his mission to transform health care, why Kamala lost, the problem with Bluesky, and much ...

French President Emmanuel Macron’s Vietnam visit and Swedish automaker Volvo Cars’ layoffs are both, in some ways, responses ...

On another issue, President Trump signed the Take It Down Act, which targets revenge porn and deepfakes. While it can be ...

Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...

The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- ...